heart failure
Conditions
Interventions
1:C-HSS (100ml) combined with furosemide (40mg)
2:furosemide (40mg)
Sponsors
Cangzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. decompensated HF (dyspnoea, weakness, lower limb edema or anasarca) and chronic ischemic or non ischemic cardiomyopathy according to the definition of HF; Framingham criteria, and New York Heart Association functional classification for HF; 2. Be unresponsive to treatment with high doses of furosemide, spironolactone, angiotensin- converting enzyme (ACE) inhibitors, digitalis, and nitrates (reduction of urine volume, a constant increase of body weight (BW), and impairments caused by clinical HF as reported above, in spite of an increase in furosemide and a combination of other diuretics); 3. had started this therapy >6 months before hospitalization; and 4. left ventricular ejection fraction (EF) < 40%, serum creatinine (Scr) < 2 mg/dl, blood urea nitrogen (BUN) < 50 mg/dl, and urinary volume < 500 ml/day.
Exclusion criteria
Exclusion criteria: Exclusion criteria were age III or < III on admission or with NYHA class III at discharge; failure to follow the prescribed treatment; did not participate in scheduled clinical interviews, did not follow the prescribed diet, or serious water or activity restrictions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| survival;hospital stay,;readmission rate;mortality rate;diuretic resistance;the renin-angiotensin-aldosterone system (RAAS); | — |
Countries
China
Contacts
Public ContactYanfang Wan
Cangzhou Central Hospital
Outcome results
None listed